Review



tmp195  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    TargetMol tmp195
    Fig. 7. HDAC9 expression is elevated in AAD aortic tissue. Mechanistically, HDAC9 binds to the promoter regions of SOD2 and IGFBP3, transcriptionally suppressing their expression, forming the HDAC9-SOD2/IGFBP3 axis, regulating the phenotypic transformation, proliferation, apoptosis, and invasion of VSMCs during the process of AAD occurrence. <t>TMP195</t> reverses this process by inhibiting HDAC9, suppressing the formation and development of AAD.
    Tmp195, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/TMP195/pm38460370-110-0-4
    Average 92 stars, based on 2 article reviews
    tmp195 - by Bioz Stars, 2026-11
    92/100 stars

    Images

    1) Product Images from "Histone deacetylase 9-mediated phenotypic transformation of vascular smooth muscle cells is a potential target for treating aortic aneurysm/dissection."

    Article Title: Histone deacetylase 9-mediated phenotypic transformation of vascular smooth muscle cells is a potential target for treating aortic aneurysm/dissection.

    Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    doi: 10.1016/j.biopha.2024.116396

    Fig. 7. HDAC9 expression is elevated in AAD aortic tissue. Mechanistically, HDAC9 binds to the promoter regions of SOD2 and IGFBP3, transcriptionally suppressing their expression, forming the HDAC9-SOD2/IGFBP3 axis, regulating the phenotypic transformation, proliferation, apoptosis, and invasion of VSMCs during the process of AAD occurrence. TMP195 reverses this process by inhibiting HDAC9, suppressing the formation and development of AAD.
    Figure Legend Snippet: Fig. 7. HDAC9 expression is elevated in AAD aortic tissue. Mechanistically, HDAC9 binds to the promoter regions of SOD2 and IGFBP3, transcriptionally suppressing their expression, forming the HDAC9-SOD2/IGFBP3 axis, regulating the phenotypic transformation, proliferation, apoptosis, and invasion of VSMCs during the process of AAD occurrence. TMP195 reverses this process by inhibiting HDAC9, suppressing the formation and development of AAD.

    Techniques Used: Expressing, Transformation Assay

    Related Articles

    Control:

    Article Title: Histone deacetylase 9-mediated phenotypic transformation of vascular smooth muscle cells is a potential target for treating aortic aneurysm/dissection.
    Article Snippet: At 4 weeks of age, experimental mice received BAPN (Sigma-Aldrich, St Louis, MO, USA) in their daily drinking water at a concentration of 0.25% for a duration of 4 weeks to induce AAD. .. TMP195 (50 mg/kg; Cat#T3983; TargetMol) or a control solvent (5% DMSO + 30% PEG300 + 5% Tween-80 + 60% Saline) was administered daily via intraperitoneal injection daily for 4 weeks. ..

    Solvent:

    Article Title: Histone deacetylase 9-mediated phenotypic transformation of vascular smooth muscle cells is a potential target for treating aortic aneurysm/dissection.
    Article Snippet: At 4 weeks of age, experimental mice received BAPN (Sigma-Aldrich, St Louis, MO, USA) in their daily drinking water at a concentration of 0.25% for a duration of 4 weeks to induce AAD. .. TMP195 (50 mg/kg; Cat#T3983; TargetMol) or a control solvent (5% DMSO + 30% PEG300 + 5% Tween-80 + 60% Saline) was administered daily via intraperitoneal injection daily for 4 weeks. ..

    Saline:

    Article Title: Histone deacetylase 9-mediated phenotypic transformation of vascular smooth muscle cells is a potential target for treating aortic aneurysm/dissection.
    Article Snippet: At 4 weeks of age, experimental mice received BAPN (Sigma-Aldrich, St Louis, MO, USA) in their daily drinking water at a concentration of 0.25% for a duration of 4 weeks to induce AAD. .. TMP195 (50 mg/kg; Cat#T3983; TargetMol) or a control solvent (5% DMSO + 30% PEG300 + 5% Tween-80 + 60% Saline) was administered daily via intraperitoneal injection daily for 4 weeks. ..

    Injection:

    Article Title: Histone deacetylase 9-mediated phenotypic transformation of vascular smooth muscle cells is a potential target for treating aortic aneurysm/dissection.
    Article Snippet: At 4 weeks of age, experimental mice received BAPN (Sigma-Aldrich, St Louis, MO, USA) in their daily drinking water at a concentration of 0.25% for a duration of 4 weeks to induce AAD. .. TMP195 (50 mg/kg; Cat#T3983; TargetMol) or a control solvent (5% DMSO + 30% PEG300 + 5% Tween-80 + 60% Saline) was administered daily via intraperitoneal injection daily for 4 weeks. ..



    Similar Products

    94
    BOC Sciences dmso
    ( A ) 4 dpci <t>DMSO-treated</t> <t>and</t> <t>TGF-β</t> inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .
    Dmso, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/Di-TMP+(Ditrimethylolpropane)+Plant/pmc13649710-439-23-20
    Average 94 stars, based on 1 article reviews
    dmso - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol recombinant human fibroblast growth factor basic
    ( A ) 4 dpci <t>DMSO-treated</t> <t>and</t> <t>TGF-β</t> inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .
    Recombinant Human Fibroblast Growth Factor Basic, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/FGF-2+Protein%2C+Bovine%2C+Recombinant/pm42119810-136-34-39
    Average 94 stars, based on 1 article reviews
    recombinant human fibroblast growth factor basic - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress tmp
    ( A ) 4 dpci <t>DMSO-treated</t> <t>and</t> <t>TGF-β</t> inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .
    Tmp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/Ligustrazine/pmc12992534-74-0-14
    Average 94 stars, based on 1 article reviews
    tmp - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol recombinant human vascular endothelial growth factor 165
    ( A ) 4 dpci <t>DMSO-treated</t> <t>and</t> <t>TGF-β</t> inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .
    Recombinant Human Vascular Endothelial Growth Factor 165, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/VEGF165+Protein%2C+Human%2C+Recombinant/pm42176839-49-24-32
    Average 94 stars, based on 1 article reviews
    recombinant human vascular endothelial growth factor 165 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Liofilchem tmp smx
    ( A ) 4 dpci <t>DMSO-treated</t> <t>and</t> <t>TGF-β</t> inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .
    Tmp Smx, supplied by Liofilchem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/smx+tmp/pm42066543-43-1-15
    Average 86 stars, based on 1 article reviews
    tmp smx - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Fisher Scientific trimethoprim tmp
    ( A ) 4 dpci <t>DMSO-treated</t> <t>and</t> <t>TGF-β</t> inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .
    Trimethoprim Tmp, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/trimethoprim/10__1002_slash_cmtd__202500165-136-0-5
    Average 86 stars, based on 1 article reviews
    trimethoprim tmp - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    91
    Sterlitech corporation transmembrane pressure tmp
    ( A ) 4 dpci <t>DMSO-treated</t> <t>and</t> <t>TGF-β</t> inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .
    Transmembrane Pressure Tmp, supplied by Sterlitech corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/TAMI+Ceramic+Membrane+Complete+Disc-Holder/10__1016_slash_j__ceja__2026__101171-109-16-12
    Average 91 stars, based on 1 article reviews
    transmembrane pressure tmp - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    94
    MedChemExpress trimethylphosphate tmp
    ( A ) 4 dpci <t>DMSO-treated</t> <t>and</t> <t>TGF-β</t> inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .
    Trimethylphosphate Tmp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/Trimethyl+phosphate/10__1016_slash_j__colsurfa__2026__140609-192-22-43
    Average 94 stars, based on 1 article reviews
    trimethylphosphate tmp - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Tokyo Chemical Industry tmp
    ( A ) 4 dpci <t>DMSO-treated</t> <t>and</t> <t>TGF-β</t> inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .
    Tmp, supplied by Tokyo Chemical Industry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/tmp/pm41892445-178-0-7
    Average 86 stars, based on 1 article reviews
    tmp - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Inari Medical Inc o procedimento indicado foi tmp com o sistema clottriever
    Radioscopia demonstra o <t>procedimento</t> de remoção de trombo da veia femoral profunda esquerda. (A) Inserido pela veia femoral comum direita, o introdutor longo 6Fr x 55cm foi posicionado na origem da veia femoral profunda esquerda. Pelo introdutor longo, o cateter Fogarty n° 4 foi inserido, posicionado no segmento distal da veia femoral comum esquerda e insuflado com contraste diluído em solução fisiológica; (B) O <t>sistema</t> <t>ClotTriever®</t> foi posicionado aberto no segmento ilíaco esquerdo e o conjunto introdutor-Fogarty foi tracionado até a veia femoral comum.
    O Procedimento Indicado Foi Tmp Com O Sistema Clottriever, supplied by Inari Medical Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tmp/clottriever+system/pmc13021007-78-0-9
    Average 86 stars, based on 1 article reviews
    o procedimento indicado foi tmp com o sistema clottriever - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) 4 dpci DMSO-treated and TGF-β inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .

    Journal: EMBO Reports

    Article Title: Sulf1 regulates inflammation via modulation of TGF-β dependent epicardial activation

    doi: 10.1038/s44319-026-00910-5

    Figure Lengend Snippet: ( A ) 4 dpci DMSO-treated and TGF-β inhibitor-treated ventricular sections stained for MyHC (CMs, green), mCherry (macrophages, magenta), and DAPI (DNA, blue). Arrowheads point to mpeg1.1 :mCherryF + cells. ( B ) Number of mpeg1.1 :mCherryF + cells per mm 2 injured area in DMSO-treated ( n = 6) and TGFβ inhibitor-treated ( n = 5) ventricles at 4 dpci. ( C ) RT-qPCR analysis of tnfa, il6 and il1b mRNA levels in control (Ctrl) ( n = 4) and TGF-β inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( D ) RT-qPCR analysis of ccl20a.3 and cdaa mRNA levels in control (Ctrl) ( n = 5) and TGFβ inhibitor-treated ( n = 5) cryoinjured ventricles at 4 dpci. ( E ) 4 dpci sulf1 +/+ , sulf1 +/+ dexamethasone-treated (DEX), sulf1 −/− and sulf1 −/− dexamethasone-treated ventricular sections stained for pSmad3 (magenta) and DAPI (DNA, blue). Arrowheads point to pSmad3 + cells. ( F ) Number of pSmad3 + cells per mm 2 injured area in sulf1 +/+ ( n = 4), sulf1 +/+ dexamethasone-treated ( n = 4), sulf1 −/− ( n = 5) and sulf1 −/− dexamethasone-treated ( n = 6) ventricles at 4 dpci. ( G ) 30 dpci sulf1 −/− DMSO-treated and sulf1 −/− dexamethasone-treated ventricular sections stained with AFOG for muscle (yellow), collagen (blue), and fibrin (red). ( H ) Percentage representation of groups of different fibrotic area sizes at 30 dpci for cryoinjured sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles. Black dotted lines delineate the area with collagen and fibrin deposits. ( I ) Percentage of collagen/fibrin in fibrotic area in sulf1 −/− DMSO-treated ( n = 6) and sulf1 −/− dexamethasone-treated ( n = 5) ventricles at 30 dpci. Scale bars: 100 µm. White dashed lines delineate the injured area. Statistical tests: Nonparametric Mann–Whitney test ( C , D ), Student’s t test ( B , F , I ). For the boxplots, the center line indicates the median; the box bounds represent the 25th and 75th percentiles; the whiskers extend to the most extreme data points; and each point represents an independent measurement. .

    Article Snippet: For the TGF-β inhibitor experiment, fish were incubated in system water supplemented with TGF-β inhibitor (Cat. no. SB431542, 50 mg BOC Sciences) or DMSO at a concentration of 10 μM per fish starting 1 day prior to cryoinjuries until 4 dpci when the hearts were extracted.

    Techniques: Staining, Quantitative RT-PCR, Analysis, Control, MANN-WHITNEY

    Radioscopia demonstra o procedimento de remoção de trombo da veia femoral profunda esquerda. (A) Inserido pela veia femoral comum direita, o introdutor longo 6Fr x 55cm foi posicionado na origem da veia femoral profunda esquerda. Pelo introdutor longo, o cateter Fogarty n° 4 foi inserido, posicionado no segmento distal da veia femoral comum esquerda e insuflado com contraste diluído em solução fisiológica; (B) O sistema ClotTriever® foi posicionado aberto no segmento ilíaco esquerdo e o conjunto introdutor-Fogarty foi tracionado até a veia femoral comum.

    Journal: Jornal Vascular Brasileiro

    Article Title: Percutaneous mechanical thrombectomy in a patient with extensive deep vein thrombosis: pioneering surgery in the northern region

    doi: 10.1590/1677-5449.202501162

    Figure Lengend Snippet: Radioscopia demonstra o procedimento de remoção de trombo da veia femoral profunda esquerda. (A) Inserido pela veia femoral comum direita, o introdutor longo 6Fr x 55cm foi posicionado na origem da veia femoral profunda esquerda. Pelo introdutor longo, o cateter Fogarty n° 4 foi inserido, posicionado no segmento distal da veia femoral comum esquerda e insuflado com contraste diluído em solução fisiológica; (B) O sistema ClotTriever® foi posicionado aberto no segmento ilíaco esquerdo e o conjunto introdutor-Fogarty foi tracionado até a veia femoral comum.

    Article Snippet: O procedimento indicado foi TMP com o sistema ClotTriever® (Inari Medical, Inc., EUA), abrangendo os segmentos cavo-ilíaco e fêmoro-poplíteo do MIE.

    Techniques: